Carnosine treatment in combination with ACE inhibition in diabetic rats

Regulatory Peptides

Volumn 194-195, Issue , 2014, Pages 36-40

  Peters, V ^a   Riedl, E ^a   Braunagel, M ^a   Hoger S ^a   Hauske, S ^a   Pfister, F ^a   Zschocke, J ^b   Lanthaler, B ^b   Benck, U ^a   Hammes, H P ^a   Kramer B K ^a   Schmitt, C P ^a   Yard, B A ^a   Koppel H ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Carnosine; Cataract; Diabetes mellitus; Diabetic nephropathy; Proteinuria

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ALBUMIN; ANSERINE; BIOLOGICAL MARKER; CARNOSINE; CN1 PROTEIN; HEMOGLOBIN A1C; LISINOPRIL; N ACETYLGLUCOSAMINE; UNCLASSIFIED DRUG; ADVANCED GLYCATION END PRODUCT; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATARACT; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DISEASE SEVERITY; DRUG EFFECT; GLUCOSE HOMEOSTASIS; GLUCOSURIA; HEMOGLOBIN BLOOD LEVEL; KIDNEY STRUCTURE; MALE; NONHUMAN; PODOCYTE; PROTEIN BLOOD LEVEL; RAT; URINARY EXCRETION; WEIGHT GAIN; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DIABETES MELLITUS, EXPERIMENTAL; KIDNEY DISEASE; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

MUS; RATTUS;

ANIMALS; CARNOSINE; DIABETES MELLITUS, EXPERIMENTAL; GLYCOSYLATION END PRODUCTS, ADVANCED; KIDNEY DISEASES; LISINOPRIL; MALE; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN;

EID: 84921415596     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2014.09.005     Document Type: Article

References (32)

1. Harvey J.N. Trends in the prevalence of diabetic nephropathy in type 1 and type 2 diabetes. Curr Opin Nephrol Hypertens 2003, 3:317-322.
2. Usrds: The United States renal data system. Am J Kidney Dis 2003, 6(Suppl. 5):1-230.
3. Tylicki L., Lizakowski S., Rutkowski B. Renin-angiotensin-aldosterone system blockade for nephroprotection: Current evidence and future directions. J Nephrol 2012, 6:900-910.
4. Vivian E., Mannebach C. Therapeutic approaches to slowing the progression of diabetic nephropathy - is less best?. Drugs in Context 2013, 212249.
5. Klahr S., Morrissey J. Comparative effects of ace inhibition and angiotensin ii receptor blockade in the prevention of renal damage. Kidney Int Suppl 2002, 82:S23-S26.
6. Janssen B., Hohenadel D., Brinkkoetter P., et al. Carnosine as a protective factor in diabetic nephropathy: Association with a leucine repeat of the carnosinase gene cndp1. Diabetes 2005, 8:2320-2327.
7. Teufel M., Saudek V., Ledig J.P., et al. Sequence identification and characterization of human carnosinase and a closely related non-specific dipeptidase. J Biol Chem 2003, 8:6251-6531.
8. Peters V., Jansen E.E., Jakobs C., et al. Anserine inhibits carnosine degradation but in human serum carnosinase (CN1) is not correlated with histidine dipeptide concentration. Clin Chim Acta 2011, 3-4:263-267.
9. Peters V., Kebbewar M., Jansen E.W., et al. Relevance of allosteric conformations and homocarnosine concentration on carnosinase activity. Amino Acids 2010, 5:1607-1615.
10. Boldyrev A. Does carnosine possess direct antioxidant activity?. Int J Biochem 1993, 8:1101-1107.
11. Mozdzan M., Szemraj J., Rysz J., et al. Antioxidant properties of carnosine re-evaluated with oxidizing systems involving iron and copper ions. Basic Clin Pharmacol Toxicol 2005, 96:352-360.
12. Alhamdani M., Al-Azzawie H.F., Abbas F.K. Decreased formation of advanced glycation end-products in peritoneal fluid by carnosine and related peptides. Perit Dial Int 2007, 1:86-89.
13. Aldini G., Orioli M., Rossoni G., et al. The carbonyl scavenger carnosine ameliorates dyslipidemia and renal function in Zucker obese rats. J Cell Mol Med 2011, 15:1339-13354.
14. Sauerhöfer S., Yuan G., Braun G.S., et al. L-carnosine, a substrate of carnosinase-1, influences glucose metabolism. Diabetes 2007, 10:2425-2432.
15. Hou W., Chen H.J., Lin Y.H. Antioxidant peptides with angiotensin converting enzyme inhibitory activities and applications for angiotensin converting enzyme purification. J Agric Food Chem 2003, 6:1706-17093.
16. Hipkiss A. Carnosine, a protective, anti-ageing peptide?. Int J Biochem Cell Biol 1998, 863-886.
17. Hu Y.Y., Ye S.D. Experimental models of type 2 diabetic nephropathy. Chin Med J 2013, 3:574-577.
18. Kang M.J., Ingram A., Ly H., et al. Effects of diabetes and hypertension on glomerular transforming growth factor-beta receptor expression. Kidney Int 2000, 4:1677-1685.
19. Obermueller N., Kranzlin B., Blum W.F., et al. An endocytosis defect as a possible cause of proteinuria in polycystic kidney disease. Am J Physiol Renal Physiol 2001, 280:F244-F253.
20. Schönherr J. Analysis of products of animal origin in feeds by determination of carnosine and related dipeptides by high-performance liquid chromatography. J Agric Food Chem 2002, 7:1945-1950.
21. Peters V., Schmitt C.P., Zschocke J., et al. Carnosine treatment largely prevents alterations of renal carnosine metabolism in diabetic mice. Amino Acids 2012, 6:2411-2416.
22. Ansurudeen I., Sunkari V.G., Grunler J., et al. Carnosine enhances diabetic wound healing in the db/db mouse model of type 2 diabetes. Amino Acids 2012, 1:127-134.
23. Pfister F., Riedl E., Wang Q., et al. Oral carnosine supplementation prevents vascular damage in experimental diabetic retinopathy. Cell Physiol Biochem 2011, 1:125-136.
24. Riedl E., Pfister F., Braunagel M., et al. Carnosine prevents apoptosis of glomerular cells and podocyte loss in stz diabetic rats. Cell Physiol Biochem 2011, 2:279-288.
25. Aldini G., Orioli M., Rossoni G., et al. The carbonyl scavenger carnosine ameliorates dyslipidaemia and renal function in zucker obese rats. J Cell Mol Med 2011, 6:1339-1354.
26. Menini S., Iacobini C., Ricci C., et al. D-carnosine octylester attenuates atherosclerosis and renal disease in ApoE null mice fed a western diet through reduction of carbonyl stress and inflammation. Br J Pharmacol 2012, 4:1344-1356.
27. Fried L.F., Emanuele N., Zhang J.H., et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013, 20:1892-1903.
28. Babizhayev M.A., Lankin V.Z., Savel'Yeva E.L., et al. Diabetes mellitus: Novel insights, analysis and interpretation of pathophysiology and complications management with imidazole-containing peptidomimetic antioxidants. Recent Pat Drug Deliv Formul 2013, 3:216-256.
29. James L.R., Ingram A., Ly H., et al. Angiotensin II activates the GFAT promoter in mesangial cells. Am J Physiol Renal Physiol 2001, 1:F151-F162.
30. Macconi D., Sangalli F., Bonomelli M., et al. Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition. Am J Pathol 2009, 3:797-807.
31. Kriz W., Gretz N., Lemley K.V. Progression of glomerular diseases: Is the podocyte the culprit?. Kidney Int 1998, 3:687-697.
32. Meyer T.W., Bennett P.H., Nelson R.G. Podocyte number predicts long-term urinary albumin excretion in pima indians with type II diabetes and microalbuminuria. Diabetologia 1999, 11:1341-1344.